The present prospective clinical study shows that stage I–IV CKD and ESKD are associated with decreased intestinal expression of the key TJ molecular components occludin and claudin-1, implying a potential cellular mechanism of gut barrier dysfunction leading to endotoxemia and systemic inflammation. The gene discussed is CLDN1; the disease is serum lipopolysaccharide activity.